Cargando…

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encodes full-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rauch, Susanne, Roth, Nicole, Schwendt, Kim, Fotin-Mleczek, Mariola, Mueller, Stefan O., Petsch, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052455/ https://www.ncbi.nlm.nih.gov/pubmed/33863911 http://dx.doi.org/10.1038/s41541-021-00311-w

Ejemplares similares

A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
por: Lenart, Klara, et al.
Publicado: (2022)

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
por: Hoffmann, Donata, et al.
Publicado: (2021)

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
por: Wolz, Olaf-Oliver, et al.
Publicado: (2022)

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses
por: Roth, Nicole, et al.
Publicado: (2022)

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
por: Kremsner, Peter G, et al.
Publicado: (2022)

Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
por: Edwards, Darin K., et al.
Publicado: (2017)

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
por: Kremsner, Peter G., et al.
Publicado: (2021)

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
por: Ascaso-del-Rio, Ana, et al.
Publicado: (2022)

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
por: Fotin-Mleczek, Mariola, et al.
Publicado: (2014)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Neutralisation of SARS‐CoV‐2 by anatomical embalming solutions
por: Quondamatteo, Fabio, et al.
Publicado: (2021)

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
por: Thess, Andreas, et al.
Publicado: (2015)

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
por: Corleis, Björn, et al.
Publicado: (2023)

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

New BVR photometry of six prominent RS CVn binaries
por: Padmakar, et al.
Publicado: (1999)

Neutralisation de Sars-CoV-2 Delta après vaccination hétérologue
por: Manus, Jean-Marie
Publicado: (2021)

SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

SARS-CoV-2 neutralising antibodies in Dogs and Cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
por: Pang, Natalie Yan-Lin, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
por: Barnes, Thomas W., et al.
Publicado: (2021)

Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays
por: Hyseni, Inesa, et al.
Publicado: (2020)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies
por: Müller, Katharina, et al.
Publicado: (2021)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities
por: Moyet, J., et al.
Publicado: (2021)

Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
por: Davis, Samantha K, et al.
Publicado: (2022)

Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera
por: Brandolini, Martina, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uj99akd2s9h9km3boer5qdtomq